CompletedInterventionalNot ApplicableUpdated Jun 26, 2019
Comparison of the PrimAry Long Versus Short Coverage With Drug-Eluting Stents for Long FemoRopopliteal Artery DiseasE (PARADE II):... | NCT02701881 | Trialant
Unknown statusInterventionalPhase 4Updated Feb 15, 2019
Comparison of the PrimAry Long Versus Short Coverage With Drug-Eluting Stents for Long FemoRopopliteal Artery DiseasE (PARADE II): Investigator-initiated Clinical Study
ClinicalTrials.gov ID
NCT02701881
Lead Sponsor
Yonsei UniversityOTHER
Overall Status
Unknown status
Study Type
Interventional
Phase
Phase 4
Enrollment
220Estimated
Last Update Posted
Feb 15, 2019Actual
Start Date
Jan 2016
Primary Completion Date
Aug 2021Estimated
Completion Date
Aug 2021Estimated
Brief Summary
Prospective, randomized, controlled, multi-center study
A total of 220 subjects with long femoropopliteal lesions will be included according to inclusion and exclusion criteria.
Patients will be randomized in a 1:1 manner into long stenting group versus short stenting group. and treated with Zilver PTX for long femoropopliteal lesions
Patients will be followed clinically for 1 year after the procedure.
Image study follow-up (Duplex US or CT angiography) will be performed at 1 year.
Femoropopliteal Artery Disease
Long stenting using drug-eluting stent (Zilver PTX)
Spot stenting using drug-eluting stent (Zilver PTX)
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Clinical criteria:
Age 19 years of older
Symptomatic peripheral artery disease:
Moderate or severe claudication (Rutherford category 2 or 3)
Critical limb ischemia (Rutherford category 4 or 5)
Patients with signed informed consent
Anatomical criteria:
Target lesion length ≥150 mm by angiographic estimation
Stenosis of more than 50% in femoropopliteal artery
At least one patent (less than 50 percent stenosed) tibioperoneal runoff vessel.
Exclusion Criteria:
A. Clinical criteria
Acute critical limb ischemia
Severe critical limb ischemia (Rutherford category 6)
Major bleeding history within prior 2 months
Known hypersensitivity or contraindication to any of the following medications: heparin, aspirin, clopidogrel or contrast agents
Age > 85 years
Severe hepatic dysfunction (> 3 times normal reference values)